| Nortriptyline | hsa00030 | Pentose phosphate pathway | 1.08E-05 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Nortriptyline | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
| Nortriptyline | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
| Nortriptyline | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
| Nortriptyline | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | |
| Nortriptyline | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Nortriptyline | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | |
| Nortriptyline | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Nortriptyline | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
| Nortriptyline | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Nortriptyline | hsa01230 | Biosynthesis of amino acids | 2.22E-03 | 4 | P51854, P60891, Q99707, P37837 | TKTL1, PRPS1, MTR, TALDO1 | More | |
| Nortriptyline | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | |
| Nortriptyline | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
| Nortriptyline | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | |
| Nortriptyline | hsa03008 | Ribosome biogenesis in eukaryotes | 1.88E-02 | 3 | O14980, O60832, Q9BVP2 | XPO1, DKC1, GNL3 | More | |
| Nortriptyline | hsa03013 | RNA transport | 2.35E-05 | 10 | O14980, P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, Q14240, P23588, Q9Y6A5 | XPO1, NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF4A2, EIF4B, TACC3 | More | |
| Nortriptyline | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
| Nortriptyline | hsa03050 | Proteasome | 1.21E-02 | 1 | P28074 | PSMB5 | More | |
| Nortriptyline | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | |
| Nortriptyline | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | |
| Nortriptyline | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | |
| Nortriptyline | hsa04064 | NF-kappa B signaling pathway | 7.27E-04 | 11 | Q13489, Q13546, P14778, P19174, Q04759, Q9UDY8, P06239, P09341, P19875, Q06643, Q9UNE0 | BIRC3, RIPK1, IL1R1, PLCG1, PRKCQ, MALT1, LCK, CXCL1, CXCL2, LTB, EDAR | More | |
| Nortriptyline | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | |
| Nortriptyline | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | |
| Nortriptyline | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Nortriptyline | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | |
| Nortriptyline | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Nortriptyline | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | |
| Nortriptyline | hsa04211 | Longevity regulating pathway | 1.18E-02 | 3 | Q12778, Q9UEF7, Q96KQ7 | FOXO1, KL, EHMT2 | More | |
| Nortriptyline | hsa04213 | Longevity regulating pathway - multiple species | 4.41E-03 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | |
| Nortriptyline | hsa04217 | Necroptosis | 1.85E-03 | 7 | P01375, P01568, P48023, Q13489, Q13546, Q14765, Q99878 | TNF, IFNA21, FASLG, BIRC3, RIPK1, STAT4, H2AC14 | More | |
| Nortriptyline | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | |
| Nortriptyline | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Nortriptyline | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
| Nortriptyline | hsa04610 | Complement and coagulation cascades | 2.78E-03 | 1 | P0C0L4 | C4A | More | |
| Nortriptyline | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Nortriptyline | hsa04613 | Neutrophil extracellular trap formation | 2.15E-05 | 11 | P11215, Q13547, P04908, Q93077, P58876, P62807, Q16778, O60814, P68431, O43315, Q16539 | ITGAM, HDAC1, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | |
| Nortriptyline | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | |
| Nortriptyline | hsa04621 | NOD-like receptor signaling pathway | 4.72E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | |
| Nortriptyline | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
| Nortriptyline | hsa04623 | Cytosolic DNA-sensing pathway | 2.20E-03 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
| Nortriptyline | hsa04640 | Hematopoietic cell lineage | 1.54E-03 | 9 | P21926, P14778, P27930, P11215, P25063, P07766, P01732, P01730, P09564 | CD9, IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD4, CD7 | More | |
| Nortriptyline | hsa04650 | Natural killer cell mediated cytotoxicity | 5.49E-06 | 12 | P19174, P01375, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, P26717, Q14953, P26715 | PLCG1, TNF, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, KLRC2, KIR2DS5, KLRC1 | More | |
| Nortriptyline | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | |
| Nortriptyline | hsa04658 | Th1 and Th2 cell differentiation | 2.21E-04 | 8 | Q04759, P07766, P20963, P19174, P06239, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, PLCG1, LCK, TBX21, IL2RB, RUNX3 | More | |
| Nortriptyline | hsa04659 | Th17 cell differentiation | 1.25E-03 | 8 | Q04759, P19174, P06239, P14784, P14778, Q9UL17, P07766, P20963 | PRKCQ, PLCG1, LCK, IL2RB, IL1R1, TBX21, CD3E, CD247 | More | |
| Nortriptyline | hsa04660 | T cell receptor signaling pathway | 3.37E-03 | 8 | Q04759, P42338, P19174, P07766, P20963, P01732, Q13191, P06239 | PRKCQ, PIK3CB, PLCG1, CD3E, CD247, CD8A, CBLB, LCK | More | |
| Nortriptyline | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Nortriptyline | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
| Nortriptyline | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Nortriptyline | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
| Nortriptyline | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
| Nortriptyline | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | |
| Nortriptyline | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Nortriptyline | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | |
| Nortriptyline | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Nortriptyline | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
| Nortriptyline | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Nortriptyline | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | |
| Nortriptyline | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Nortriptyline | hsa04966 | Collecting duct acid secretion | 1.68E-02 | 2 | P02730, P00918 | SLC4A1, CA2 | More | |
| Nortriptyline | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Nortriptyline | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | |
| Nortriptyline | hsa04975 | Fat digestion and absorption | 2.80E-02 | 1 | O14494 | PLPP1 | More | |
| Nortriptyline | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | |
| Nortriptyline | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | |
| Nortriptyline | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | |
| Nortriptyline | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | |
| Nortriptyline | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Nortriptyline | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Nortriptyline | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | |
| Nortriptyline | hsa05132 | Salmonella infection | 9.85E-03 | 4 | Q13546, Q13489, O60282, P68371 | RIPK1, BIRC3, KIF5C, TUBB2C | More | |
| Nortriptyline | hsa05133 | Pertussis | 4.94E-02 | 1 | P0C0L4 | C4A | More | |
| Nortriptyline | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | |
| Nortriptyline | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
| Nortriptyline | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | |
| Nortriptyline | hsa05146 | Amoebiasis | 2.05E-05 | 11 | P09341, P19875, P14778, P27930, P01375, P42338, P11215, P05089, P30679, P22694, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1 | More | |
| Nortriptyline | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Nortriptyline | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | |
| Nortriptyline | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | |
| Nortriptyline | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Nortriptyline | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
| Nortriptyline | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | |
| Nortriptyline | hsa05218 | Melanoma | 1.07E-02 | 3 | P09619, Q9GZP0, Q02750 | PDGFRB, PDGFD, MAP2K1 | More | |
| Nortriptyline | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | |
| Nortriptyline | hsa05231 | Choline metabolism in cancer | 9.39E-03 | 4 | Q02750, P09619, Q9GZP0, O15245 | MAP2K1, PDGFRB, PDGFD, SLC22A1 | More | |
| Nortriptyline | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.99E-04 | 8 | P42338, P19174, P07766, P20963, P06239, Q04759, Q9HC35, P01730 | PIK3CB, PLCG1, CD3E, CD247, LCK, PRKCQ, EML4, CD4 | More | |
| Nortriptyline | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Nortriptyline | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Nortriptyline | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Nortriptyline | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
| Nortriptyline | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | |
| Nortriptyline | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 3.10E-02 | 3 | Q8IZS8, P54284, P13612 | CACNA2D3, CACNB3, ITGA4 | More | |
| Nortriptyline | hsa05414 | Dilated cardiomyopathy | 2.11E-02 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | |
| Nortriptyline | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | |
